多发性骨髓瘤患者的自体干细胞移植：利用模式和医院效果。
Autologous stem cell transplantation in multiple myeloma patients: utilization patterns and hospital effects.
机构信息
Division of Clinical Epidemiology and Aging Research, German Cancer Research Center (DKFZ), Heidelberg, Germany.
Medizinische Klinik V, University Hospital Heidelberg, Heidelberg, Germany.
出版信息
Leuk Lymphoma. 2020 Oct;61(10):2365-2374. doi: 10.1080/10428194.2020.1768383. Epub 2020 May 30.
Evidence on volume outcome associations for autologous stem cell transplantation (ASCT) in multiple myeloma (MM) is limited. We investigated ASCT utilization patterns and volume outcome associations in the German National Registry for Stem Cell Transplants (DRST). MM patients with an upfront ASCT between 1998 and 2014 registered in the DRST were included. ASCT utilization increased strongly from 6% to 17% between 1999 and 2013 with the largest increase for patients aged 60-64 years (8-34%). The mean number of ASCTs conducted in the hospitals per year varied (quintiles, Q1:0.0-8.2 to Q5:31.0-102.7). Center volume was not associated with survival after upfront ASCT (lowest vs. highest center volume, hazard ratios and 95% confidence intervals: 0.95 (0.76-1.18), = 0.92). Our findings may reflect a high standard of care and degree of specialization of centers performing ASCT for MM in Germany.
关于自体干细胞移植（ASCT）在多发性骨髓瘤（MM）中的体积疗效相关性的证据有限。我们研究了德国干细胞移植注册中心（DRST）中 ASCT 的使用模式和体积疗效相关性。在 DRST 中登记的 1998 年至 2014 年期间接受首次 ASCT 的 MM 患者被纳入研究。1999 年至 2013 年，ASCT 的使用率从 6%大幅增加到 17%，其中 60-64 岁患者的增长率最高（8-34%）。医院每年进行的 ASCT 数量存在差异（五分位数，Q1：0.0-8.2 至 Q5：31.0-102.7）。中心容量与首次 ASCT 后的生存无关（最低与最高中心容量，风险比和 95%置信区间：0.95（0.76-1.18），=0.92）。我们的发现可能反映了德国进行 MM ASCT 的中心的高护理标准和专业化程度。
Zotero 插件